• +1-646-491-9876
    • +91-20-67278686

    Search

    Integrin Alpha 7 Pipeline Review H1 2017

    Integrin Alpha 7 Pipeline Review H1 2017

    • Report Code ID: RW0001851078
    • Category Life Sciences
    • No. of Pages 25
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Integrin Alpha 7 (ITGA7) - Pipeline Review, H1 2017

    Summary

    According to the recently published report 'Integrin Alpha 7 (ITGA7) - Pipeline Review, H1 2017'; Integrin Alpha 7 (ITGA7) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies.

    Integrin Alpha 7 (ITGA7) - Alpha-7 integrin is a protein encoded by the ITGA7 gene. It induces changes in the shape and mobility of myoblasts, and facilitates their localization at laminin-rich sites of secondary fiber formation. It is involved in the maintenance of the myofibers cytoarchitecture as well as for their anchorage, viability and functional integrity.

    The report 'Integrin Alpha 7 (ITGA7) - Pipeline Review, H1 2017' outlays comprehensive information on the Integrin Alpha 7 (ITGA7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

    It also reviews key players involved in Integrin Alpha 7 (ITGA7) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 4 and 4 respectively. Report covers products from therapy areas Musculoskeletal Disorders and Genetic Disorders which include indications Muscular Dystrophy and Duchenne Muscular Dystrophy.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Integrin Alpha 7 (ITGA7)
    - The report reviews Integrin Alpha 7 (ITGA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Integrin Alpha 7 (ITGA7) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Integrin Alpha 7 (ITGA7) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Integrin Alpha 7 (ITGA7) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Integrin Alpha 7 (ITGA7)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Integrin Alpha 7 (ITGA7) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Integrin Alpha 7 (ITGA7) - Overview
    Integrin Alpha 7 (ITGA7) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Integrin Alpha 7 (ITGA7) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Molecule Type
    Integrin Alpha 7 (ITGA7) - Companies Involved in Therapeutics Development
    Strykagen Corp
    Integrin Alpha 7 (ITGA7) - Drug Profiles
    Stryka-232 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Stryka-234 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Stryka-425 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Stryka-516 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Stryka-516s - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Stryka-533 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Stryka-969 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Stryka-978 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    StrykaPro-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indication, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Strykagen Corp, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indications, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Strykagen Corp

    Request for Sample

    Report Url https://www.reportsweb.com//integrin-alpha-7-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//integrin-alpha-7-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//integrin-alpha-7-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments